Carisoprodol (Soma)

Safety Summary

Regulatory Status

Sources

These citations are the ones recorded for the human adult context.

• US DEA: Carisoprodol (Soma) — Schedule IV Classification (2012), Meprobamate Metabolite Mechanism, 'Soma Coma' Polysubstance Abuse Combination, Withdrawal Seizure Risk, and Prescribing Patterns in Southern US States (2022) REGULATORY · 2022
• US FDA: Carisoprodol — Prescribing Information, 2–3 Week Maximum Duration, Meprobamate Hepatic Metabolism, Physical Dependence and Withdrawal, Schedule IV Controlled Status, and Pediatric Contraindication (<16 Years) (2022) REGULATORY · 2022
• OEHHA Proposition 65 List of Carcinogens or Reproductive Toxicants (CSV, list date 31-Jul-26) REGULATORY
• Permissible Exposure Limits – OSHA Annotated Table Z-1 REGULATORY
• EPA CompTox CTX API: predicted properties for DTXSID8024733 (Carisoprodol (Soma)) REFERENCE

Same data as the API response, which is open and needs no key. The full per-record source list is available to authenticated callers.